Crossmark

Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)

Crossref DOI link: https://doi.org/10.1038/s41409-022-01748-w

Published Online: 2022-07-14

Published Print: 2022-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Maffini, Enrico

Labopin, Myriam https://orcid.org/0000-0003-4514-4748
Beelen, Dietrich Wilhelm https://orcid.org/0000-0001-5050-220X
Kroeger, Nicolaus https://orcid.org/0000-0001-5103-9966
Arat, Mutlu https://orcid.org/0000-0003-2039-8557
Wilson, Keith M. O.

Bay, Jacques-Olivier

Ganser, Arnold

Martin, Hans

Passweg, Jakob

Kottaridis, Panagiotis D.

Yakoub-Agha, Ibrahim https://orcid.org/0000-0003-4524-8782
Porras, Rocio Parody

Wagner, Eva Maria

Esteve, Jordi https://orcid.org/0000-0002-8056-648X
Lanza, Francesco https://orcid.org/0000-0002-5189-7167
Nagler, Arnon https://orcid.org/0000-0002-0763-1265
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
License Information

Text and Data Mining valid from 2022-07-14

Version of Record valid from 2022-07-14
More Information

Article History

Received: 29 September 2021

Revised: 14 June 2022

Accepted: 27 June 2022

First Online: 14 July 2022

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below